Kala Bio, Inc. (KALA): Shareholders' Equity
$7.00M
As of 2025-12-31
$9.04M
As of 2026-06-30
-28.3%
3-year compound annual growth
-41.3%
5-year compound annual growth
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $7.00M | -43.3% | 2026-04-15, Balance as of period end |
| 2024-12-31 | $12.33M | +64.3% | 2026-04-15, Balance as of period end |
| 2023-12-31 | $7.50M | -60.5% | 2025-03-31, Balance as of period end |
| 2022-12-31 | $18.97M | +12.9% | 2024-03-29, Balance as of period end |
| 2021-12-31 | $16.80M | -83.2% | 2023-03-03, Balance as of period end |
| 2020-12-31 | $100.00M | +236.8% | 2022-03-29, Balance as of period end |
| 2019-12-31 | $29.69M | -71.7% | 2021-02-25, Balance as of period end |
| 2018-12-31 | $104.98M | +17.1% | 2020-02-12, Balance as of period end |
| 2017-12-31 | $89.68M | n/m | 2019-03-12, Balance as of period end |
| 2016-12-31 | -$87.76M | n/m | 2018-04-02, Balance as of period end |
| 2015-12-31 | -$56.66M | n/a | 2018-04-02, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| Kala Bio, Inc. (KALA) | 2025-12-31 | $7.00M | -43.3% |
| Abbott Laboratories (ABT) | 2025-12-31 | $52.13B | +9.4% |
| Bristol Myers Squibb Co (BMY) | 2025-12-31 | $18.47B | +13.1% |
| TherapeuticsMD, Inc. (TXMD) | 2025-12-31 | $26.88M | -1.8% |
| Eli Lilly & Co (LLY) | 2025-12-31 | $26.54B | +85.9% |
| Pfizer Inc (PFE) | 2025-12-31 | $86.78B | -1.9% |
| Johnson & Johnson (JNJ) | 2025-12-28 | $81.54B | +14.1% |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $161.55M | +0.3% |
| Merck & Co., Inc. (MRK) | 2025-12-31 | $52.66B | +13.6% |
Compare KALA, ABT, BMY, TXMD side by side · Screen every company in Pharmaceutical Preparations ↗